Comparing the current results to its competitors, Biophytis Sa reported Revenue increase in the 4 quarter 2023 by 0 % year on year, while most of its competitors have experienced contraction in revenues by -3.22 %, achieved in the same quarter.
Biophytis Sa, slower than the average decrease reported by the company's competitors of -42.2 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -42.2 %
Biophytis Sa's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, which is characterized by rapid technological advancements and a focus on proprietary products. It competes with major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. Competitors may possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, marketing, recruitment of qualified personnel, establishment of clinical trial sites, patient registration, and acquisition of complementary technologies. Industry mergers and acquisitions may lead to resource concentration among fewer competitors. Smaller or early-stage companies also represent significant competition.
Reata Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapeutics for serious and life-threatening diseases. Their business model centers around the discovery, development, and commercialization of novel drugs based on their proprietary technology platform. Reata Pharmaceuticals aims to bring transformative treatments to patients, partnering with other organizations and leveraging their expertise to deliver value to stakeholders.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Pacira Biosciences Inc is a pharmaceutical company that focuses on the development and commercialization of non-opioid pain management products and treatments.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Panbela Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative and effective treatments for pancreatic cancer. They aim to leverage their expertise in drug development and strategic partnerships to bring novel therapies to the market and address the unmet medical needs of patients with this devastating disease.
Sources:
Biophytis Sa’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biophytis Sa versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
